2gz9

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Line 1: Line 1:
[[Image:2gz9.gif|left|200px]]
[[Image:2gz9.gif|left|200px]]
-
{{Structure
+
<!--
-
|PDB= 2gz9 |SIZE=350|CAPTION= <scene name='initialview01'>2gz9</scene>, resolution 2.17&Aring;
+
The line below this paragraph, containing "STRUCTURE_2gz9", creates the "Structure Box" on the page.
-
|SITE=
+
You may change the PDB parameter (which sets the PDB file loaded into the applet)
-
|LIGAND=
+
or the SCENE parameter (which sets the initial scene displayed when the page is loaded),
-
|ACTIVITY=
+
or leave the SCENE parameter empty for the default display.
-
|GENE=
+
-->
-
|DOMAIN=
+
{{STRUCTURE_2gz9| PDB=2gz9 | SCENE= }}
-
|RELATEDENTRY=[[2gz7|2GZ7]], [[2gz8|2GZ8]]
+
-
|RESOURCES=<span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=2gz9 FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=2gz9 OCA], [http://www.ebi.ac.uk/pdbsum/2gz9 PDBsum], [http://www.rcsb.org/pdb/explore.do?structureId=2gz9 RCSB]</span>
+
-
}}
+
'''Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of SARS-CoV Main Protease'''
'''Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of SARS-CoV Main Protease'''
Line 27: Line 24:
[[Category: Lu, I L.]]
[[Category: Lu, I L.]]
[[Category: Wu, S Y.]]
[[Category: Wu, S Y.]]
-
[[Category: sars cov main protease]]
+
[[Category: Sars cov main protease]]
-
 
+
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sun May 4 05:40:53 2008''
-
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Mar 31 03:23:14 2008''
+

Revision as of 02:40, 4 May 2008

Template:STRUCTURE 2gz9

Structure-Based Drug Design and Structural Biology Study of Novel Nonpeptide Inhibitors of SARS-CoV Main Protease


Overview

Severe acute respiratory syndrome coronavirus (SARS-CoV) main protease (M(pro)), a protein required for the maturation of SARS-CoV, is vital for its life cycle, making it an attractive target for structure-based drug design of anti-SARS drugs. The structure-based virtual screening of a chemical database containing 58,855 compounds followed by the testing of potential compounds for SARS-CoV M(pro) inhibition leads to two hit compounds. The core structures of these two hits, defined by the docking study, are used for further analogue search. Twenty-one analogues derived from these two hits exhibited IC50 values below 50 microM, with the most potent one showing 0.3 microM. Furthermore, the complex structures of two potent inhibitors with SARS-CoV M(pro) were solved by X-ray crystallography. They bind to the protein in a distinct manner compared to all published SARS-CoV M(pro) complex structures. They inhibit SARS-CoV M(pro) activity via intensive H-bond network and hydrophobic interactions, without the formation of a covalent bond. Interestingly, the most potent inhibitor induces protein conformational changes, and the inhibition mechanisms, particularly the disruption of catalytic dyad (His41 and Cys145), are elaborated.

About this Structure

2GZ9 is a Single protein structure of sequence from Sars coronavirus. Full crystallographic information is available from OCA.

Reference

Structure-based drug design and structural biology study of novel nonpeptide inhibitors of severe acute respiratory syndrome coronavirus main protease., Lu IL, Mahindroo N, Liang PH, Peng YH, Kuo CJ, Tsai KC, Hsieh HP, Chao YS, Wu SY, J Med Chem. 2006 Aug 24;49(17):5154-61. PMID:16913704 Page seeded by OCA on Sun May 4 05:40:53 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Personal tools